Clinicopathological Features and Molecular Analysis of Primary Glioblastomas in Moroccan Patients
- PDF / 182,411 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 19 Downloads / 196 Views
Clinicopathological Features and Molecular Analysis of Primary Glioblastomas in Moroccan Patients Said Hilmani & Omar Abidi & Houda Benrahma & Mehdi Karkouri & Souha Sahraoui & Abdessamad El Azhari & Abdelhamid Barakat
Received: 3 July 2012 / Accepted: 25 July 2012 / Published online: 4 August 2012 # Springer Science+Business Media, LLC 2012
Abstract Glioblastoma is the most frequent and most aggressive primary brain tumor. Primary and secondary glioblastomas develop through different genetic pathways. The aim of this study was to determinate the genetic and clinical features of primary glioblastoma in Moroccan patients. The blood and tumor samples were obtained from a group of 34 Moroccan patients affected with primary glioblastoma. The tumors were investigated for TP53, IDH1, and IDH2 mutations using PCR sequencing analysis. Clinicopathological data showed that the mean age at diagnosis of patients was 50.06 years, the sex ratio was 11 F/23 M, and the median of Karnofsky performance score was 60. About 18 % of patients were initially treated by total tumor resection, 41 % by subtotal, and 38 % by partial resection, but biopsy was performed for a single patient (3 %). Twenty-five patients (74 %) received radiotherapy. In addition, the
median survival of the all patients was 13 months following diagnosis. There was a significant impact of higher Karnofsky performance score (KPS) (≥80) on overall survival, plog-rank test00.0002, whereas other parameters did not show any significant differences. The molecular analysis revealed TP53 mutations in 3/34 (8.82 %) cases; R273H, R306X, and Q136X. However, none of the analyzed samples contained the R132-IDH1 or R172-IDH2 mutations. These results showed the absence of IDH1 mutation in primary glioblastoma, confirming that this mutation is a hallmark of secondary glioblastoma. It can be used to distinguish primary from secondary glioblastomas. We found also that higher KPS was a significantly favorable factor in patients with primary glioblastoma. Keywords Primary glioblastoma . TP53 . IDH1 and IDH2 . Clinical features . Prognosis impact . Morocco
Said Hilmani and Omar Abidi contributed equally to this work. O. Abidi (*) : H. Benrahma : A. Barakat Laboratoire de Génétique Moléculaire Humaine, Département de la Recherche Scientifique, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco e-mail: [email protected] S. Hilmani : A. El Azhari Service de Neurochirurgie, Centre Hospitalier Universitaire Ibn Rochd, Casablanca, Morocco M. Karkouri Laboratoire d’Anatomopathologie, Centre Hospitalier Universitaire Ibn Rochd, Casablanca, Morocco S. Sahraoui Centre d’Oncologie et Radiothérapie, Centre Hospitalier Universitaire Ibn Rochd, Casablanca, Morocco
Introduction Glioblastoma (GBM) is the most common and most aggressive primary brain tumor that, despite current therapies, the median survival continues to be approximately 12 months following diagnosis (Fine 1994). GBM may be primary (de novo), in 95 % of cases, when develop rapidly after a short clinical
Data Loading...
